Castle Biosciences, a Texas-based cancer diagnostics company, has unveiled DecisionDx-GBM, a molecular brain cancer diagnostic test. It is developed at and licensed from The University of Texas M. D. Anderson Cancer Center.
The test is used to prospectively predict patient outcome to treatment for glioblastoma multiforme (GBM), the most common form of primary brain cancer.
Howard Colman one of the co-inventors, said: “Our goal in developing the first application of this biomarker panel was to be able to prospectively identify GBM patients most likely to have a durable response to standard therapy. The data indicate that the DecisionDx-GBM assay can serve as the basis for a robust clinical test (amenable to paraffin tissue) which, along with existing clinical and other molecular markers, could be used to optimize therapeutic choices for individual patients, analogous to the predictive test developed for optimization of patient therapy in breast cancer.”
Derek Maetzold, president and CEO of Castle Biosciences, said: “We are committed to bringing the promise of personalized medicine to patients afflicted with underserved orphan cancers by developing tests that assist the physician in achieving better outcomes for their patients. DecisionDx-GBM is the first steps towards achieving this goal.”